P2X7 antagonist programme, EVT 401, to a top tier global animal health company partnered

Exclusive license granted to major animal health company for development of Evotec proprietary compound

15-Aug-2011 - Germany

Evotec AG announced that it has entered into a world-wide license and collaboration agreement with a top tier animal health company that intends to develop the proprietary Evotec compound EVT401, a selective, small molecule P2X7 antagonist, in the companion animal market.

Evotec is entitled to receive a technology- transfer payment, development and commercial milestone payments, and tiered royalties on net sales. Evotec retains all rights to the programme for human therapeutic use.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are very pleased to be partnering with a company that has proven capabilities for developing drug candidates for animal indications. This deal not only gives us additional product value, but also nicely proves the strength of our medicinal chemistry approach. We look forward to closely collaborate with this top animal health company to make this product development a success."

Financial details related to the agreement are not being disclosed. 

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances